These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11785073)

  • 1. [Diferelin treatment of primary local and generalized cancer of the prostate].
    Kolesnikov GP; Rusakov IG; Shaplygin LV; Voznesenskiĭ SA; Bystrov AA
    Urologiia; 2001; (6):17-9. PubMed ID: 11785073
    [No Abstract]   [Full Text] [Related]  

  • 2. Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer.
    Krongrad A; Brady J; Rodriguez RJ
    South Med J; 1997 Apr; 90(4):460-1. PubMed ID: 9114847
    [No Abstract]   [Full Text] [Related]  

  • 3. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
    Smith MR; Zietman AL; Finkelstein JS; Wu CL
    N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
    [No Abstract]   [Full Text] [Related]  

  • 4. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
    Daskivich TJ; Oh WK
    Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A
    Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A; Di Silverio F
    Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
    Matveev BP; Bukharkin BV
    Urologiia; 2001; (6):20-1. PubMed ID: 11785074
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of orbital metastasis from prostatic carcinoma as an initial symptom.
    Isshiki S; Cho S; Matsuno D; Sato N; Furuya Y
    Hinyokika Kiyo; 2007 Mar; 53(3):193-5. PubMed ID: 17447492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
    deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
    Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
    Akyol F; Ozyigit G; Selek U; Karabulut E
    Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer.
    Furuya Y; Cho S; Ohta S; Sato N; Kotake T; Masai M
    J Urol; 2001 Jul; 166(1):213. PubMed ID: 11435864
    [No Abstract]   [Full Text] [Related]  

  • 14. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.
    Procopio G; Guadalupi V; Giganti MO; Mariani L; Salvioni R; Nicolai N; Capone F; Valdagni R; Bajetta E
    BJU Int; 2011 Jul; 108(2):223-7. PubMed ID: 21078047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial comment.
    Türkeri L
    Can J Urol; 2010 Jun; 17(3):5169. PubMed ID: 20566008
    [No Abstract]   [Full Text] [Related]  

  • 17. False elevations in prostate-specific antigen levels affecting patient management.
    Kummar S; Shafi NQ
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):599-601; discussion 602. PubMed ID: 16163243
    [No Abstract]   [Full Text] [Related]  

  • 18. Biochemical remission after resection of prostate cancer lung metastasis.
    Chao DH; Higgins JP; Brooks JD
    Urology; 2004 Mar; 63(3):584-5. PubMed ID: 15028469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Quality of life of patients with prostatic cancer under hormonal therapy].
    Aliaev IuG; Aslamazov EG; Demidko IuL
    Urologiia; 2010; (1):46, 48-51. PubMed ID: 20891045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy.
    Behrakis P; Koutsilieris M
    Anticancer Res; 1997; 17(3A):1517-8. PubMed ID: 9179189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.